top of page
PARTNERS WITH
Regorafenib
Tyrosine kinase inhibitors
MECHANISM OF ACTION
VEGF receptor TKI
MECHANISM OF KIDNEY INJURY
AKI not well described
CLINICAL KIDNEY SYNDROME
Hypertension, Fanconi's Syndrome
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
Hypophosphatemia, hypocalcemia, hyponatremia, and hypokalemia
RISK FACTORS
n/a
MITIGATION STRATEGIES
unclear
SUGGESTIONS
Hold offending drug and rechallenge after AKI/proteinuria resolves, Discontinue offending drug, Add ACEi/ARB, Check UA with urine culture, Check urine protein creatinine ratio, check electrolytes, replace electrolytes.
NOTES/COMMENTS
PHARMACOKINETICS
Molecular Weight
Volume of Distribution
Plasma Protein Binding
Metabolism
Bioavailability
Half-life elimination
Time to peak
Excretion
Dialyzable?
Unknown
REF:
PMID: 29318210, 19332223, 25981818, 23177514
PATHOLOGY SLIDES:
ENTRY UPDATES:
Raad Chowdhury
MN/USA
Sep 25, 2022
bottom of page